Kiley Juergens Wealth Management LLC Invests $589,000 in Abbott Laboratories $ABT

Kiley Juergens Wealth Management LLC bought a new position in shares of Abbott Laboratories (NYSE:ABT) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,735 shares of the healthcare product maker’s stock, valued at approximately $589,000.

A number of other institutional investors have also bought and sold shares of ABT. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. BTIG Research reiterated a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. Oppenheimer reduced their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $95.80 on Wednesday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average price of $89.10 and a 200-day moving average price of $103.74. The company has a market cap of $166.86 billion, a PE ratio of 26.83, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Insider Activity

In other news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.